Loader

Pathways

PathWhiz ID Pathway Meta Data

PW176741

Pw176741 View Pathway
drug action

Chlorprothixene H1-Antihistamine Blood Vessel Constriction Action Pathway

Homo sapiens
Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. Chlorprothixene inhibits the H1 histamine receptor on blood vessel endothelial cells. This normally activates the Gq signalling cascade which activates phospholipase C which catalyzes the production of Inositol 1,4,5-trisphosphate (IP3) and Diacylglycerol (DAG). Because of the inhibition, IP3 doesn't activate the release of calcium from the sarcoplasmic reticulum, and DAG doesn't activate the release of calcium into the cytosol of the endothelial cell. This causes a low concentration of calcium in the cytosol, and it, therefore, cannot bind to calmodulin. Calcium bound calmodulin is required for the activation of the calmodulin-binding domain of nitric oxide synthase. The inhibition of nitric oxide synthesis prevents the activation of myosin light chain phosphatase. This causes an accumulation of myosin light chain-phosphate which causes the muscle to contract and the blood vessel to constrict, decreasing the swelling and fluid leakage from the blood vessels caused by allergens.

PW176496

Pw176496 View Pathway
metabolic

Chlorprothixene Predicted Metabolism Pathway

Homo sapiens
Metabolites of Chlorprothixene are predicted with biotransformer.

PW128189

Pw128189 View Pathway
drug action

Chlorprothixene Serotonin Antagonist Action Pathway

Homo sapiens
Chlorprothixene is a thioxanthene antipsychotic. Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis.

PW146644

Pw146644 View Pathway
drug action

Chlorquinaldol Drug Metabolism Action Pathway

Homo sapiens

PW128373

Pw128373 View Pathway
drug action

Chlortetracycline Action Pathway

Homo sapiens
Chlortetracycline is a tetracycline antibiotic commonly used for veterinary practice, that is commonly administered via topical ointment. Chlortetracycline acts by competing for the A site of the bacterial ribosome, by doing so the tRNA cannot bind to the site and thus no more amino acids cannot be added to the peptide chain. Ultimately leading to protein synthesis and halting growth and reproduction, as proteins cannot be synthesized that are necessary for bacteria cell reproduction.

PW145973

Pw145973 View Pathway
drug action

Chlortetracycline Drug Metabolism Action Pathway

Homo sapiens

PW176192

Pw176192 View Pathway
metabolic

Chlortetracycline Predicted Metabolism Pathway

Homo sapiens
Metabolites of Chlortetracycline are predicted with biotransformer.

PW000340

Pw000340 View Pathway
drug action

Chlorthalidone Action Pathway

Homo sapiens
Chlorthalidone (also known as chlorthalidone or phthalamudine) is an organic compound that used for diuretic. It can inhibit the solute carrier family 12 member 3 (also known as sodium-chloride symporter) in the nephron to prevent water reabsorption. Solute carrier family 12 member 3 is also used for sodium reabsorption that count for 5% of total amount. Solute carrier family 12 member 3 transports chloride and sodium from lumen to epithelial cell, and sodium/potassium ATPases facilitate the export of sodium to basolateral interstitium to provide sodium gradient that will increase the osmolarity in interstitium, which lead to establishment of osmotic gradient for water reabsorption.

PW124496

Pw124496 View Pathway
drug action

Chlorthalidone Diuretic Action Pathway

Homo sapiens
Chlorthalidone is an oral diuretic drug which acts in the kidney, specifically in the distal convoluted tubule of the nephron. Chlorthalidone is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. In the distal convoluted tubule (DCT), the regulation of ions such as sodium, potassium, calcium, chloride, and magnesium occurs. In epithelial cells of the DCT, the basolateral membrane consists of the Na+/K+ ATPase, which pumps Na+ into the interstitium-blood area and K+ into the epithelial cell; the Na+/Ca2+ exchanger, which pumps Na+ into the cell and Ca2+ into the interstitium-blood; and the chloride transporter which transports chloride into the interstitium-blood. The apical membrane contains a calcium channel that transports calcium from the lumen into the epithelial cell, a potassium channel that transports K+ out of the epithelial cell, and a Na+/Cl- cotransporter which transports Na+ and Cl- into the epithelial cell. Chlorthalidone targets this Na+/Cl- cotransporter. Chlorthalidone is transported from the blood into the epithelial cells, then is transported into the urine through the multidrug-resistant associated protein-4. In the lumen, it has access to the Na+/Cl- transporter and inhibits it preventing Na+ reabsorption. The inhibition of Na+ reabsorption results in a low cytosolic concentration of Na+ and increases the solute concentration of the lumen. This decreases the lumen-epithelial cell concentration gradient and as a result, less water would be reabsorbed from the urine. This effect is valued in conditions such as hypertension because it allows more water to be excreted in the urine rather than be absorbed in the blood which increases blood volume. Side effects such as nausea, vomiting, stomach cramping, diarrhea, constipation, loss of appetite, dizziness, headache, and increased thirst can occur from taking chlorthalidone. This drug is administered as an oral tablet.

PW144438

Pw144438 View Pathway
drug action

Chlorthalidone Drug Metabolism Action Pathway

Homo sapiens